ArticleInternational journal for parasitology. Drugs and drug resistance2020
Efficacy evaluation of anthelmintic products against an infection with the canine hookworm (Ancylostoma caninum) isolate Worthy 4.1F3P in dogs.
Article in International journal for parasitology. Drugs and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Fluorescence videography for the rapid and automated in-clinic detection of microfilariae.Parasites & vectors · 2026Article
- The detection of three independent benzimidazole resistance mutations in a single Ancylostoma caninum population from a Golden Retriever breeding kennel in Sao Paulo, Brazil.International journal for parasitology. Drugs and drug resistance · 2026Article
- Efficacy of a single oral administration of a formulation of fluralaner, moxidectin and pyrantel (BRAVECTO® TriUNO) in dogs for the treatment and prevention of angiostrongylosis.Parasites & vectors · 2026Article
- Evolution of Ivermectin Resistance in the Nematode ModelEvolutionary applications · 2026Article
- Efficacy evaluation of a new oral chewable tablet containing fluralaner, moxidectin, and pyrantel (BRAVECTOParasites & vectors · 2026Article
- High prevalence of gastrointestinal parasites in dogs from Saipan, Northern Mariana Islands, including the zoonotic Ancylostoma ceylanicum.Parasites & vectors · 2026Article
- Local field study on the effectiveness and safety of milbemycin oxime and lotilaner (CredelioParasitology research · 2025Article
- Parasitological survey ofOpen veterinary journal · 2025Article
- Anthelmintic Resistance in Ancylostoma caninum: A Comprehensive Review.Veterinary medicine and science · 2025Review
- Differential Emodepside Efficacy in Drug-Resistant and Drug-SusceptibleTropical medicine and infectious disease · 2025Article
- Efficacy of Simparica Trio® against induced infections of Ancylostoma braziliense and Ancylostoma ceylanicum in dogs.Parasites & vectors · 2025Article
- Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the treatment and control of hookworm infections in dogs.Parasites & vectors · 2025Article
- Potential of emodepside for vector-borne disease control.Malaria journal · 2025Article
- Efficacy of Anthelmintics Against Canine Hookworm Infections in the Bono East Region of Ghana.Journal of parasitology research · 2025Article
- Coprological assessment of domestic carnivores in public areas and health education focused on larva migrans in São Paulo State, Brazil.Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria · 2025Article
- Smells Like Anthelmintic Resistance-Gastrointestinal Prevalence, Burden and Diversity in Dogs from Portugal.Pathogens (Basel, Switzerland) · 2024Article
- Evaluation of Parasight All-in-One system for the automated enumeration of helminth ova in canine and feline feces.Parasites & vectors · 2024Article
- Challenges in establishing small animal models formicroPublication biology · 2024Article
- Multiple anthelmintic drug resistant Ancylostoma caninum in foxhounds.International journal for parasitology. Drugs and drug resistance · 2023Article
- An efficient method for viable cryopreservation and recovery of hookworms and other gastrointestinal nematodes in the laboratory.International journal for parasitology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ancylostoma caninum is the most prevalent intestinal nematode of dogs, and has a zoonotic potential. Multiple-drug resistance (MDR) has been confirmed in a number of A. caninum isolates, including isolate Worthy 4.1F3P, against all anthelmintic drug classes approved for hookworm treatment in dogs in the United States (US). The cyclooctadepsipeptide emodepside is not registered to use in dogs in the US, but in a number of other countries/regions. The objective of this study was to evaluate the efficacy of emodepside + praziquantel, as well as three commercial products that are commonly used in the US for treatment of hookworms, against a suspected (subsequently confirmed) MDR A. caninum isolate Worthy 4.1F3P. 40 dogs infected on study day (SD) 0 with 300 third-stage larvae, were randomly allocated to one of five treatment groups with eight dogs each: pyrantel pamoate (Nemex®-2), fenbendazole (Panacur® C), milbemycin oxime (Interceptor®), emodepside + praziquantel tablets and non-treated control. Fecal egg counts (FEC) were performed on SDs 19, 20, 22, 27, 31 and 34. All treatments were administered as per label requirements on SD 24 to dogs in Groups 1 through 4. Two additional treatments were administered on SDs 25 and 26 to dogs in Group 2 as per label requirements. Dogs were necropsied on SD 34 and the digestive tract was removed/processed for worm recovery and enumeration. The geometric mean (GM) worm counts for the control group was 97.4, and for the pyrantel pamoate, fenbendazole, milbemycin oxime, and emodepside + praziquantel groups were 74.8, 72.0, 88.9, and 0.4, respectively. These yielded efficacies of 23.2%, 26.1%, and 8.8%, and 99.6%, respectively. These data support previous findings of the MDR status of Worthy 4.1F3P as treatments with pyrantel pamoate, fenbendazole and milbemycin oxime lacked efficacy. In sharp contrast, Worthy 4.1F3P was highly susceptible to treatment with emodepside + praziquantel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.